Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr 2;73(5):94.
doi: 10.1007/s00262-024-03665-x.

Bifidobacterium modulation of tumor immunotherapy and its mechanism

Affiliations
Review

Bifidobacterium modulation of tumor immunotherapy and its mechanism

Bo Pei et al. Cancer Immunol Immunother. .

Abstract

The advent of tumor immunotherapy in patients has revolutionized the treatment of tumors and significantly improved survival rates for a wide range of tumors. However, the full therapeutic potential of immune checkpoint inhibitors (ICIs) has yet to be realized, as not all patients have a lasting survival benefit from them, and a significant proportion of patients show primary or acquired resistance to immunotherapy. Bifidobacterium is one of the most common probiotics, and its antitumor and immunomodulatory effects have been demonstrated in recent years, but its immunomodulatory effects in tumors, especially on ICIs and in combination, have not been extensively studied in clinical practice, and its effects on the immune system and the mechanisms that modulate immunotherapy are largely unknown. Therefore, this review will focus on the immunomodulatory effects of Bifidobacteria in malignancies and the possible mechanisms of action of Bifidobacteria on immunotherapy in the hope of providing a basis for further research and better application of Bifidobacteria in clinical practice.

Keywords: Bifidobacterium; Gut probiotics; Immune checkpoint inhibitors; Immunotherapy; Mechanism.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Fig. 1
Fig. 1
Bifidobacterium-modulatory cancer immunotherapy
Fig. 2
Fig. 2
Modulatory effects of Bifidobacteria in cancer immunotherapy

Similar articles

Cited by

References

    1. Morgan E, Arnold M, Gini A et al (2023) Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut 72(2):338–344 - PubMed
    1. Badowski C, He B, Garmire LX (2022) Blood-derived lncRNAs as biomarkers for cancer diagnosis: the good, the bad and the beauty. NPJ Precis Oncol 6(1):40 - PMC - PubMed
    1. Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A (2023) Colorectal cancer statistics, 2023. CA Cancer J Clin 73(3):233–254 - PubMed
    1. DeSantis CE, Miller KD, Dale W et al (2019) Cancer statistics for adults aged 85 years and older, 2019. CA Cancer J Clin 69(6):452–467 - PubMed
    1. LeMasters T, Madhavan SS, Sambamoorthi U, Hazard-Jenkins HW, Kelly KM, Long D (2018) Receipt of guideline-concordant care among older women with stage I-III breast cancer: a population-based study. J Natl Compr Canc Netw 16(6):703–710 - PMC - PubMed

Substances

LinkOut - more resources